Aquestive Therapeutics (AQST) Receivables - Net (2017 - 2026)

Aquestive Therapeutics' Receivables - Net history runs 10 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• In Q1 2026, Receivables - Net fell 34.25% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (down 34.25% YoY), while the FY2025 annual figure was $17.8 million, up 141.87% from the prior year.
• Receivables - Net was $6.9 million for Q1 2026 at Aquestive Therapeutics, down from $17.8 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $19.9 million in Q1 2022 to a low of $4.7 million in Q4 2022.
• Historically, Receivables - Net has averaged $10.4 million across 5 years, with a median of $9.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables - Net jumped 144.78% in 2022, then slumped 62.05% in 2023.
• A 5-year view of Receivables - Net shows it stood at $4.7 million in 2022, then climbed by 18.41% to $5.6 million in 2023, then jumped by 31.85% to $7.3 million in 2024, then soared by 141.87% to $17.8 million in 2025, then plunged by 61.34% to $6.9 million in 2026.
• The last three Receivables - Net figures came in at $6.9 million (Q1 2026), $17.8 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.